John Marshall, MD, reviews the case of a patient with metastatic HER2+ (human epidermal growth factor receptor 2) gastroesophageal junction cancer.
Video Programs
Jamile Shammo, MD, reviews initial treatment options for patients with low risk polycythemia vera.
Advertisement
Dr. Ruben Mesa and panel discuss the importance of and methods for risk assessment in patients with polycythemia vera.
Experts in MPN discuss diagnostic considerations for polycythemia vera.
Prithviraj Bose, MD, reviews the case of a 57-year-old man diagnosed with polycythemia vera.
Advertisement
Andrew G. Gianoukakis, MD, of Harbor-UCLA Medical Center, describes the rationale for treating a patient with RAI-refractory differentiated thyroid cancer with systemic therapy.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Savolitinib Plus Osimertinib Improves PFS, OS in MET-Driven NSCLC
2
T-DXd Improves PFS vs Standard of Care in First-Line HER2-Mutant NSCLC
3
FDA Grants Fast Track Designation to Piktor in Endometrial Cancer
4
FDA Grants Type C Meeting for OST-HER2 OS Data in Osteosarcoma
5